ROYALTY PHARMA UBS Global Healthcare Conference Terrance Coyne, EVP, Chief Financial Officer Marshall Urist, EVP, Co-Head of Research & Investments May 24, 2021 2 Forward Looking Statements & Non-GAAP Financial Information This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all o ...

PRE-QUARTERLY RESULTS COMMUNICATION NEW YORK, NY, April 14, 2021 - Royalty Pharma plc (Nasdaq: RPRX) intends to announce its financial results for the first quarter of 2021 on May 11, 2021. An invitation for the results webcast will follow shortly. To assist in the financial modeling of its first quarter 2021 results, the company has compiled the following items. Non-GAAP Financial Measures Royalty Pharma focuses on certain non-GAAP financial measures to manage its business. These measures, which are presen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39329 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 110 East 59 Street th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) (State or other jurisdiction of incorporation or organization) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 For the transition period from to Commission file number 001-39329 Royalty Pharma plc (Exact name of registrant as specified in its charter) England and Wales Not applicable (State or othe ...

Financial Performance - Royalty receipts are the primary measure of operating performance, encompassing cash collections from financial royalty assets and other sources [205]. - Adjusted Cash Receipts and Adjusted Cash Flow are key liquidity measures used to evaluate the company's ability to generate cash from operations [207]. - Total royalty receipts from growth products reached $567.993 million for the three months ended June 30, 2020, compared to $409.833 million in the same period of 2019, representing a 38.6% increase [220]. - Adjusted Cash Receipts for the six months ended June 30, 2020, totaled $844.1 million, down from $1,075.6 million in 2019, indicating a decrease of 21.5% [220]. - Adjusted EBITDA for the six months ended June 30, 2020, was $774.1 million, a decline of 24.7% from $1,028.5 million in 2019 [220]. - Total income and other revenues for the three months ended June 30, 2020, reached $510.9 million, an increase of $53.3 million or 11.7% year-over-year [250]. - Consolidated net income for the three months ended June 30, 2020, was $602.0 million, a significant increase of $423.2 million or 236.7% year-over-year [250]. - Net income attributable to controlling interest for the three months ended June 30, 2020, was $442.1 million, an increase of $290.4 million or 191.4% year-over-year [250]. - Adjusted Cash Flow decreased by 19.0% year-over-year to $666.498 million for the six months ended June 30, 2020 [299]. - The company reported an increase in financial royalty receipts of $108.4 million for the six months ended June 30, 2020, contributing to the overall growth in cash provided by operating activities [339]. Revenue Sources - The portfolio includes royalties on over 45 marketed therapies and four development-stage product candidates, addressing areas such as rare diseases, oncology, and diabetes [209]. - Income from financial royalty assets increased by $57.2 million to $474.2 million for the three months ended June 30, 2020, representing a 13.7% increase compared to the same period in 2019 [250]. - The cystic fibrosis franchise contributed $136.119 million in revenue for the three months ended June 30, 2020, up from $85.745 million in 2019, marking a 58.7% increase [220]. - The HIV franchise generated $64.692 million in revenue for the three months ended June 30, 2020, compared to $52.193 million in 2019, reflecting a growth of 24.0% [220]. - Royalty receipts from the cystic fibrosis franchise increased by $42.8 million, driven by the successful launch of Trikafta in the U.S. [303]. - Royalty receipts from Tysabri increased by $11.7 million, benefiting from extra shipping days and a pricing adjustment in Italy [304]. - Royalty receipts from Imbruvica increased by $31.9 million, driven by continued penetration in chronic lymphocytic leukemia patients [305]. - Royalty receipts from the HIV franchise increased by $20.0 million, primarily due to strong performance of Biktarvy [306]. Acquisitions and Investments - Royalty Pharma has deployed $12 billion to acquire royalties on approved products since its inception in 1996, with $7 billion acquired from 2012 to 2019 [195]. - The company has invested $6.1 billion in royalties on development-stage product candidates since 2012 [195]. - The company acquired a royalty on risdiplam for $650 million, which was approved by the FDA in August 2020, marking a significant addition to its portfolio [333]. - The company invested $497.2 million in royalties and related assets during the second quarter of 2020, totaling $667.3 million for the first six months of 2020, including four new investments [331]. Debt and Liquidity - The company raised $1.9 billion in net proceeds from its IPO in June 2020, significantly enhancing its liquidity position [335][343]. - As of June 30, 2020, the company had cash and cash equivalents totaling $2.4 billion, up from $283.7 million as of December 31, 2019 [344]. - The company had total long-term debt outstanding of $5.7 billion as of June 30, 2020, down from $6.0 billion as of December 31, 2019 [337]. - The company has entered into new senior secured credit facilities totaling $6.04 billion, consisting of a Term Loan A of $3.12 billion and a Term Loan B of $2.83 billion, with interest rates of 1.50% and 1.75% above LIBOR, respectively [345]. - The company is required to make total term loan amortization payments of $5.95 billion over the next five years, with $94.2 million due in the remainder of 2020 [354]. Operational Efficiency - The company operates with a capital-efficient business model, reducing exposure to common industry challenges like high R&D costs [194]. - Management emphasizes that income from royalties should not be viewed as a direct measure of near-term financial performance due to accounting volatility [204]. - The total operating expenses for the three months ended June 30, 2020, were $101.6 million, a decrease of $28.2 million or 21.7% compared to the same period in 2019 [250]. - General and administrative expenses increased by $12.5 million to $42.8 million for the three months ended June 30, 2020, reflecting a 41.0% increase compared to the same period in 2019 [250]. Regulatory Approvals - The FDA approved a supplemental New Drug Application for Erleada in September 2019, expanding its market [285]. - Vertex's cystic fibrosis franchise received FDA approval for Trikafta in October 2019, significantly expanding the addressable market and extending royalty duration to 2037 [286]. - Epizyme received FDA approval for Tazverik for relapsed or refractory follicular lymphoma, marking a significant regulatory milestone [290]. - The FDA granted accelerated approval for Trodelvy, the first antibody-drug conjugate approved specifically for metastatic triple-negative breast cancer [292].